Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01172418 · ClinicalTrials.gov registry record · Phase 4
Randomized Trial of 2 Antibody Induction Steroid Avoidance Protocols
A Phase 4 study, sponsored by University of Miami.
- Completed
- Registry status
- Phase 4
- Development phase
- 200
- Enrollment target
NCT01172418 is a Phase 4 study that has completed, run by University of Miami. The registered enrollment target is 200 participants.
The verdict
NCT01172418, a Phase 4 study, has completed, sponsored by University of Miami.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 200 participants
- Enrollment target
Study Summary
The purpose of the present study is to determine which antibody induction regimen will result in a safer and more effective method to use with steroid avoidance in renal transplant recipients. Patients receiving either first cadaveric or non-HLA identical living donor kidney transplants will be preoperatively randomized into 2 groups.
Interventions
- DRUG Alemtuzumab
- DRUG Thymoglobulin
- DRUG Daclizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2006-02 |
| Est. Completion | 2010-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01172418
The ClinicalTrials.gov registry entry for NCT01172418 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Miami, which has 721 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Alemtuzumab is the first listed.
NCT01172418 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01172418 about?
NCT01172418 is a clinical study titled "Randomized Trial of 2 Antibody Induction Steroid Avoidance Protocols". The purpose of the present study is to determine which antibody induction regimen will result in a safer and more effective method to use with steroid avoidance in renal transplant recipients. Patients receiving either first cadaveric or non-HLA identical living donor kidney transplants will be preo...
What is the current status of trial NCT01172418?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 200 participants. The study started on 2006-02. Estimated completion is 2010-05.
What interventions are being tested in trial NCT01172418?
The interventions under investigation include: Alemtuzumab (DRUG), Thymoglobulin (DRUG), Daclizumab (DRUG).
Who is sponsoring clinical trial NCT01172418?
This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.